Summary
New research published in the New England Journal of Medicine details an experimental T-cell receptor-engineered therapy that achieved complete remission in a 17-year-old boy with advanced kidney cancer. This innovative approach targets proteins within cancer cells, showing promise for treating solid tumors previously resistant to engineered immune cell therapies.